Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 0527 • ACR Convergence 2022
Rituximab as Maintenance Therapy for ANCA-associated Vasculitides: Pooled Analysis and Long-term Outcome of MAINRITSAN Trials
Florence Delestre¹, Pierre Charles², Loïc Guillevin³, Raphaël Porcher⁴ and Benjamin Terrier³, ¹cochin Hospital, Paris, France, ²Institut Mutualiste Montsouris, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁴Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: Maintenance therapy after induction of remission has been shown to reduce relapse rate and mortality in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The three MAINRITSAN…
Abstract Number: 1083 • ACR Convergence 2022
Treatment of ANCA-associated Vasculitis with Extreme Impairment of Renal Function: A Case-Control Study Comparing an Intensive B Cell Depletion Regimen with the Standard of Care Using Oral Cyclophosphamide
Dario Roccatello¹, Savino Sciascia², Stefano Murgia¹, Giacomo Quattrocchio¹, Michela Ferro¹, Emanuele De Simone¹, Carla Naretto¹, Antonella Barreca¹, Daniela Rossi¹, Vittorio Modena¹ and Roberta Fenoglio¹, ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitis associated with antineutrophil cytoplasm antibodies (AAV) in…
Abstract Number: PP03 • ACR Convergence 2022
To Err Is Human: The Need for Patients with Rheumatic and Musculoskeletal Diseases to Continuously Monitor Their Health Care Records
Ida Hakkarinen, Greenbelt, MD
Background/Purpose: In November 1999, the Institute of Medicine issued a press release announcing publication of To Err is Human: Building a Safer Health System (Kohn…
Abstract Number: 0447 • ACR Convergence 2022
Is Systemic Vasculitis a Risk Factor for Myocardial Infarction? A Retrospective Cohort Study from the National Inpatient Sample
Kavin Raj¹, Marlene Marte Furment², Jyoti Verma³ and Keerthana Jyotheeswara Pillai⁴, ¹University of California Riverside School of Medicine, Riverside, CA, ²SUNY Upstate University Hospital, Syracuse, NY, ³Saint Peter's University Hospital, New Brunswick, NJ, ⁴Kilpauk Medical College, Chennai, India, New Brunswick, NJ
Background/Purpose: Systemic vasculitis is a group of uncommon conditions characterized by inflammation of blood vessels, leading to organ ischemia and necrosis. Although several rheumatological disorders…
Abstract Number: 0700 • ACR Convergence 2022
Accurate Identification of ANCA-Associated Vasculitis Cases from Clinical Notes Using Machine Learning
Liqing Wang¹, John Laurentiev¹, Claire Cook², Eli Miloslavsky², Hyon Choi³, Li Zhou¹ and Zachary Wallace², ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is a rare disease associated with substantial morbidity and mortality.1 To enable outcomes and comparative effectiveness studies using large, phenotypically diverse…
Abstract Number: 1085 • ACR Convergence 2022
Safety of Plasmapheresis as an Adjuvant Therapy in Severe Pediatric Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: A Single Center Cohort
Sharanya Joginpalli¹, Alvaro Orjuela², Marietta De Guzman³ and Emily Frierson², ¹Baylor College of Medicine- Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Therapeutic plasma exchange (TPE) is used in anti-neutrophil cytoplasmic antibody associated vasculitis (AAV) as adjunct treatment for severe disease. There is paucity of data…
Abstract Number: 0448 • ACR Convergence 2022
All-Cause and Cause-Specific Mortality in ANCA-Associated Vasculitis: A Population-based Study
Anna Wilding¹, Maria Weiner², Jens Rathmann³, Mårten Segelmark¹ and Aladdin Mohammad⁴, ¹Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²Nephrology, Department of Medical and Health Sciences, Linköping, Linköping University, Linköping, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund University, Lund, Skane Lan, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden
Background/Purpose: Despite improvement in treatment and early diagnosis of ANCA-associated Vasculitis (AAV), mortality remains elevated. Early deaths in AAV patients are often attributed to the…
Abstract Number: 0762 • ACR Convergence 2022
Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
Christian Ammitzboell¹, marianne Kragh thomsen², Jakob Bøgn Andersen¹, Jens Magnus Berth Jensen³, marie-Louise From Hermansen¹, anders Dahl Johannsen¹, Mads Lamm Larsen¹, Clara Elbæl Mistegaard¹, Susan Mikkelsen³, Fruzsina Szabados³, Signe Risbøl Vils¹, Christian Erikstrup³, Ellen-Margrethe Hauge¹ and Anne Troldborg¹, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Treatment with rituximab (RTX) has presented a challenge during the COVID-19 pandemic, as antibody response after primary vaccination are markedly reduced and often undetectable.The primary…
Abstract Number: 1086 • ACR Convergence 2022
Characteristics and Outcomes of Patients with ANCA Associated Vasculitis Treated with Plasma Exchange: An Analysis of the National Inpatient Sample Database
Vinit Gilvaz¹, Akil Sherif², Sonu Abraham³, Anu Saji² and Anthony Reginato⁴, ¹Brown University, East Providence, RI, ²Saint Vincent Hospital, Worcester, MA, ³Lahey Medical Center, Burlington, MA, ⁴Brown University, Providence, RI
Background/Purpose: Plasma exchange (PLEX) has been used in the management of patients with severe anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) for decades. The most recent…
Abstract Number: L14 • ACR Convergence 2021
Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis
David Jayne¹, Peter Merkel², Annette Bruchfeld³, Duvuru Geetha⁴, Alexandre Karras⁵, John Niles⁶ and Pirow Bekker⁷, ¹University of Cambridge, Cambridge, United Kingdom, ²University of Pennsylvania, Philadelphia, PA, ³Linköping University, Linköping, Sweden, ⁴Johns Hopkins University, Baltimore, MD, ⁵Hopital Europeen Georges Pompidou, Paris, France, ⁶Massachusetts General Hospital, Boston, MA, ⁷ChemoCentryx, Inc., San Carlos, CA
Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is a life- or organ-threatening condition in which patients experience severe inflammation of small blood vessels; renal disease is…
Abstract Number: 0414 • ACR Convergence 2021
Effect of Induction Therapies on Ear, Nose and Throat Involvement in Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: Results from a Multi-center Cohort Study
Roline Krol¹, Caroline Schaap¹, Paco Welsing¹, Ruth Klaasen², Hilde Remmelts², Chris Hagen², Franka van Reekum¹, Marloes Heijstek¹ and Julia Spierings¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Meander Medical Center, Amersfoort, Netherlands
Background/Purpose: Up to 87% of patients with anti-neutrophil cytoplasmic antibody (ANCA)- associated vasculitis (AAV) have ear, nose and throat (ENT) involvement, which can lead to…
Abstract Number: 0433 • ACR Convergence 2021
Use of 2-Mercaptoethane Sodium Sulfonate Prophylaxis in Cyclophosphamide-Treated Patients with ANCA-Associated Vasculitis: Results of an Electronic Survey
Lukas Joos¹, Solange Gonzalez Chiappe¹, Thomas Neumann¹ and Alfred Mahr², ¹Kantonsspital St.Gallen, St.Gallen, Switzerland, ²Kantonsspital St. Gallen, St.Gallen, Switzerland
Background/Purpose: Co-prescribing mesna with CYC for AAV aims to prevent the potential urotoxic effects of CYC. We investigated current clinical practice related to prescribing mesna…
Abstract Number: 0415 • ACR Convergence 2021
Utility of the 22-Item Sinonasal Outcome Test Patient-Reported Outcome Instrument in ANCA-Associated Vasculitis
Ellen Romich, Sherry Chou and Rennie Rhee, University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) causes sinus symptoms that impact quality of life. The 22-item Sinonasal Outcome Test (SNOT-22) is a patient-reported outcome measure to assess…
Abstract Number: 0434 • ACR Convergence 2021
Protein Profiling in Pre-dating Samples Separate MPO-ANCA Vasculitis from PR3-ANCA Vasculitis
Mikael Brink¹, Ewa Berglin¹, Aladdin Mohammad², Andrey Alexeyenko³, Kristina Lejon¹ and Solbritt Rantapaa-Dahlqvist⁴, ¹Umeå Universitet, Umeå, Sweden, ²Lund University, Lund, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Ume University, Umea, Sweden
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is considered a chronic relapsing condition, with unknown etiology. This study was undertaken to gain insight to the…
Abstract Number: 0417 • ACR Convergence 2021
Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
Rula Hajj-Ali¹, Robert Butler², Carol Langford³, Leonard Calabrese², David Cuthbertson⁴, Nader Khalidi⁵, CURRY LEE MD KOENING⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Antoine Sreih⁷, Kenneth Warrington¹³ and Peter Merkel⁷, ¹Cleveland Clinic, Hunting Valley, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic, Moreland Hills, OH, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶LIMITED TO OFFICIAL UNIVERSITY DUTIES ONLY, Salt Lake City, UT, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Brigham and Women's Hospital, Boston, MA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³Mayo Clinic, Rochester, Minnesota
Background/Purpose: The prevalence of neurologic involvement (NI) in ANCA-associated vasculitis (AAV), especially central nervous system (CNS) involvement, is not well characterized. This project aimed to…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].